A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
University of Pittsburgh
Astellas Pharma Inc
Neonc Technologies, Inc.
Essen Biotech
Takeda
Novartis
VM Oncology, LLC
NuCana plc
Medicenna Therapeutics, Inc.
OncoC4, Inc.
NextCure, Inc.
Vincerx Pharma, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
University of Florida
Kineta Inc.
National Institutes of Health Clinical Center (CC)
Incyte Corporation
MultiVir, Inc.